AbbVie Inc. (ABBV) belonging to the Medical sector has surged 0.11% and closed its last trading session at $70.6.
Currently, the stock has a 1 Year Price Target of $72.56.
The consensus recommendation, according to Zacks Investment research, is 2.31. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 2.36 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.36 and 2.5 respectively.
AbbVie Inc. reported its EPS as $1.26 with the analysts projecting the EPS of the stock as $1.2. The company beat the analyst EPS Estimate with the difference of $0.06. This shows a surprise factor of 0.05%.
Many analysts have provided their estimated foresights on AbbVie Inc. Earnings, with 17 analysts believing the company would generate an Average Estimate of $1.4.
Whereas they predicted High and Low Earnings Estimate as $1.42 and $1.36 respectively. While in the same Quarter Previous year, the Actual EPS was $1.26.
Analysts are also projecting an Average Revenue Estimate for AbbVie Inc. as $6.92 Million in the Current Quarter. This estimate is provided by 14 analysts.
The High Revenue estimate is predicted as 7.06 Million, while the Low Revenue Estimate prediction stands at 6.87 Million. The company’s last year sales total was 6.43 Million.
For the Current Quarter, the growth estimate for AbbVie Inc. is 11.1%, while for the Next Quarter the stock growth estimate is 15.7%.
In the past 5 years, the stock showed growth of 16.72% per annum. While for the next 5 years, the growth estimate is 14.45%.
Insider Trades for AbbVie Inc. show that the latest trade was made on 1 Jun 2017 where Severino (Michael), the Officer completed a transaction type “Sell” in which 21576 shares were traded at a price of $66.71.
AbbVie Inc. (ABBV) has the market capitalization of $112.35 Billion. The company rocked its 52-Week High of $70.79 and touched its 52-Week Low of $55.06.
The stock has Return on Assets (ROA) of 9.5 percent. Return on Equity (ROE) stands at 116.1% and Return on Investment (ROI) of 18 percent.
The stock is currently showing YTD performance of 12.74 Percent. The company has Beta Value of 1.54 and ATR value of 0.91. The Weekly and Monthly Volatility stands at 1.42% and 1.28%.